Epilepsia is the official journal of the International League Against Epilepsy (ILAE). The Journal publishes original articles on all aspects of epilepsy, clinical and experimental.

Editorial Policies

  1. Top of page
  2. Editorial Policies
  3. Types of Manuscripts
  4. Manuscript Preparation
  5. Manuscript Submission
  6. Manuscript Publication
  7. Supplement Publication
  8. Epilepsias Position on Issues Involved in Ethical Publication

(1) The Editors-in-Chief of Epilepsia invite manuscripts in all areas of epilepsy-related research. As a general guide, manuscripts will be considered for publication if they contribute significant new findings to the field. The primary aim of Epilepsia is to publish innovative and high quality papers that provide clinical and/or basic science insights.

The Editors will make an initial evaluation of all manuscripts for their impact on the epilepsy field, and will then determine whether a report is appropriate for the Journal. Reports are unlikely to be accepted for publication if they are not based in sound science and/or they provide only incremental knowledge of little general usefulness. To assist authors in deciding whether to submit a manuscript to Epilepsia, we provide the following commonly-encountered examples of reports which we are unlikely to publish:

  • (a)
     Regionally specific surveys (e.g., papers that describe clinical features or epidemiology in a given region of the world) that do not provide new insights into epilepsy;
  • (b)
     Correlative studies where the statistical power is too low to provide new statistically-sound findings;
  • (c)
     Genetic association studies in which the association has not been replicated;
  • (d)
     Investigatory articles (e.g., imaging studies) describing the application of a new technical variation which is not likely to have clinical utility;
  • (e)
     Correlative clinical studies which are conceived without clear hypotheses and the results of which are of little clinical utility;
  • (f)
     Basic research studies that are not grounded in epilepsy-relevant hypotheses;
  • (g)
     Simple one group, before-after evaluations of therapeutic interventions and programs that do not include a control group;
  • (h)
     Small case series (e.g., surgical findings) which largely replicate what is already known;
  • (i)
     Case reports (highly unlikely to be accepted unless they provide novel findings of theoretical or clinical importance).

Epilepsia will accept, review, and publish studies with negative results, provided that appropriate controls have been used, the study is adequately powered, and the results are important and/or useful to others in the research community.

(2) Manuscripts describing original research, and passing the initial editorial screen, will be subject to external peer review. Acceptance of these manuscripts is never guaranteed. At least two reviews are generally obtained for these submissions; additional reviews may be sought at the discretion of the Editors. Appeals of rejection decisions will be considered by the Editors-in-Chief; decisions of the Editors-in-Chief are final.

(3) Papers submitted to Epilepsia are accepted with the understanding that the material described in the manuscript has not been previously published, except in abstract form, and that it is not simultaneously under consideration by any other journal.

(4) As a condition of publication, Epilepsia requires authors to transfer copyright to the ILAE. A Copyright Assignment Form (CAF) must be provided at the time of manuscript submission (see below).

(5) Epilepsia complies with recommendations of the International Committee of Medical Journal Editors ( Authors are required to include a statement at the end of their manuscript, affirming that the work described is consistent with the Journal’s guidelines for ethical publication (see below). Epilepsia is a member of the Committee on Publication Ethics (COPE), and we adhere to its principles (

(6) Authors are also required to provide full disclosure of any conflict of interest as a part of the submitted manuscript (see Disclosure of Conflicts of Interest in the Manuscript Format section under MANUSCRIPT PREPARATION). Manuscripts that do not conform to these guidelines will not be considered for publication. Discovery of failure to comply will result in rejection of the manuscript, retraction of the published article, and/or a ban on future submissions by the author(s).

(7) In submitting a manuscript, the submitting/corresponding author must acknowledge that: a) all co-authors have been substantively involved in the study and/or the preparation of the manuscript; b) no undisclosed groups or persons have had a primary role in the study and/or in manuscript preparation (i.e., there are no “ghost-writers”); and c) all co-authors have seen and approved the submitted version of the paper and accept responsibility for its content. The Editors reserve the right to require authors to submit their original data for comparison with the manuscript’s illustrations, tables, and results.

Types of Manuscripts

  1. Top of page
  2. Editorial Policies
  3. Types of Manuscripts
  4. Manuscript Preparation
  5. Manuscript Submission
  6. Manuscript Publication
  7. Supplement Publication
  8. Epilepsias Position on Issues Involved in Ethical Publication

The following types of material may be are considered for publication:

(1) Peer-reviewed papers (to be submitted by uploading online via ScholarOne Manuscripts –

a. Critical reviews and commentary. The Editors-in-Chief encourage submission of reviews and commentary on topical and controversial issues. Authors planning/proposing such papers should consult with the Editors-in-Chief before submitting the manuscripts. While there are no strict length limits on this type of paper, manuscripts generally should be no longer than 6000 words, with no more than 5 figures/tables (combined). Longer manuscripts will be considered at the discretion of the Editors-in-Chief.

b. Full-length original research articles. These articles should be limited in length to 4750 words (including title, author information, and summary), and the figures and tables together should comprise no more than 3 journal pages. Figures and tables can be “traded” with text, according to the formula: 500 words = ½ page. Additional figures and tables can be submitted as online only Supporting Information (which will be linked to the online version of the published article). Authors should aim for presenting material clearly and completely, in the most concise and direct form possible; the Introduction should be brief and to the point, and the Discussion should be restricted to issues directly relevant to the Results.

c. Special reports. In some cases, special reports from ILAE Commissions or other broadly constituted working groups will be published after peer review. The corresponding author of such papers should confer with the Editors-in-Chief to determine if the full manuscript will be peer-reviewed, or whether only a short version will be considered for publication in Epilepsia’sGray Matters (see below).

d. Brief communications. These articles – including short studies, small series, case reports, etc. – should describe previously unpublished material, including original research and/or clinical observations. The papers are limited generally to 1600 words (including the summary), 12 references, and not more than 2 figures and tables (combined). Please note that the Editors may use their discretion to request that brief communications be shortened to a length that they feel is appropriate.

Brief Communications will be published online only (not in the print version of the journal). They will appear in a specific issue in the electronic (online) version, and will be identified and described (Short Summary) in the Table of Contents of the printed version of that issue. The online papers will be dealt with, by PubMed/Medline and other indexing/citation systems, exactly the same way as print articles; they will be referenced by their DOI number and date of online publication (which will continue to be approximately 35 working days following acceptance).

(2) Editorially-reviewed material (to be submitted by email to the Editors-in-Chief at, except letters and commentaries which should be submitted online at

Other contributions that do not report original research will be published at the discretion of the Editors-in-Chief, with only editorial review. Such material includes: obituaries, workshop reports and conference summaries, letters/commentary to the Editors (500 word limit, and only exceptionally figures or tables), special (brief) reports from ILAE Commissions or other working groups, and announcements. Such material will usually be published in Gray Matters.

(3) Supplements (to be submitted as directed by the Editors-in-Chief)

Supplements, including meeting abstracts, will be published only after advance arrangements are made with the Editors-in-Chief. Guidelines for preparing supplements are given below. Proposal for, and questions about supplements should be directed to one of the Editors-in-Chief ( Such proposals must be explicitly approved by the Editors-in- Chief, who will also confirm the page rate charge for the proposed supplement.

Manuscript Preparation

  1. Top of page
  2. Editorial Policies
  3. Types of Manuscripts
  4. Manuscript Preparation
  5. Manuscript Submission
  6. Manuscript Publication
  7. Supplement Publication
  8. Epilepsias Position on Issues Involved in Ethical Publication

(1) General Style Guidelines

Manuscripts are to be submitted (and will be published) in English. Writers not fluent in English should seek assistance to ensure proper grammar and syntax, and to help generate a manuscript organization that facilitates reader understanding. Authors for whom English is a second language may choose to have their manuscript professionally edited before submission, to improve the English. A list of independent suppliers of editing services can be found at All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication. The Editors will not re-write papers submitted in unacceptable English, and will return such manuscripts for revision before sending them out for review.

Use international non-proprietary (generic) names when referring to drugs; avoid proprietary (brand) names. All acronyms should be spelled out at first mention. Spell out numbers below 10 and all numbers that are used to begin a sentence; use Arabic numerals for numbers above 10 and for units of measure.

Word limits for each type of submission will generally be enforced unless there are good reasons not to do so. If manuscripts exceed these guidelines, authors should submit a covering letter explaining why the additional length is necessary.

(2) Manuscript Format

a. Critical Reviews and Invited Commentaries

□ Title Page (see Full-Length Original Research below)

Summary and Key Words

Reviews and commentaries should generally begin with a summary (less than 500 words) of the content. The summary (unstructured) should provide the reader with the main points of the paper. The Summary should be followed by a list of 3–6 Key Words; please provide Key Words that will assist in the indexing of your article (i.e., make it easy for individuals who are searching PubMed to find your paper). Do not use words already incorporated into your title (those words are picked up automatically by the indexing service).

□ Body of review

There is no designated structure for the body of Reviews or Commentaries. Authors are encouraged, however, to use sub-headings to separate major sections and to facilitate clarity.

Tables, figures, figure legends, references, acknowledgements, statement of compliance with the Journal’s guidelines for ethical standards in publishing, disclosure of conflicts of interest, and Supplementary material – as for Full-Length Original Research (see below)

b. Full-Length Original Research, Special Reports, and Brief Communications

Title Page

Include the following information: Full title of the manuscript; authors’ names (first and last names, middle initial when commonly used by that author); institutional affiliation for each author (use superscripted numbers after each author’s name, and a corresponding superscripted number before each institutional affiliation); contact information for the corresponding author (name, address, telephone number, fax number, e-mail address); running title (no more than 40 characters and spaces in length); key words for use by abstracting services (same as following Summary); number of text pages; number of words (including title, author information, and Summary); number and proposed size (estimated number of journal pages) of figures; number and proposed size (estimated number of journal pages) of tables.

Summary and Key Words

Provide a summary of no more than 500 words (250 words for Brief Communications). The summary of Full-Length Original Research reports should consist of four sections, labeled: Purpose; Methods; Key findings; Significance. This structured summary should concisely and specifically describe why and how the study was performed, the essential results, and what the authors conclude from the results. To promote brevity, authors may use phrases rather than complete sentences. The summary for Special Reports, Critical Reviews, Invited Commentaries, and Brief Communications is not structured, but should cover the same topics as the structured summary. The Summary (structured or unstructured) should be followed by 3–6 Key Words (see above).

Epilepsia requires a second short summary (100 words) for Brief Communications, that can be used in the print issue Table of Contents. The abbreviated summary should be submitted as a Supporting Document.


State the objectives of the study clearly and concisely, and provide a context for the study by referring judiciously to previous work in the area. Do not attempt to present a comprehensive review of the field. Provide a statement about the significance of this research for understanding and/or treating epilepsy.


Describe the research methods in sufficient detail that the work can be duplicated; alternatively, give references (if they are readily accessible) to previous comprehensive descriptions. Identify the statistical procedures that were used and the rationale for choosing a particular method, especially if it is not standard.

Reports of experimental studies on humans must explicitly certify that the research received prior approval by the appropriate institutional review body and that informed consent was obtained from each volunteer or patient. Studies involving animals must include an explicit statement that animal care and use conformed to institutional policies and guidelines. When animals are subjected to invasive procedures, details must be provided regarding the steps taken to eliminate/minimize pain and suffering, including the specific anesthetics, analgesics, or other drugs used for that purpose (amounts, mode of delivery, frequency of administration).

If extensive descriptions of methods are needed, provide basic information within the text and submit supplementary information for online Supporting Information.

□ Results

Results should be reported fully and concisely, in a logical order. Do not repeat methodological details from the Methods section. Where possible, use figures and/or tables to present the data in a clear and concise format. Do not repeat data in the text that are given in a table, but refer to the table. Provide textual explanations for all figures, with clear reference to the figure(s) under discussion. Descriptive information provided in figure legends need not be repeated in the text; use the text, however, to describe key features of the figures. When appropriate, give sample numbers, the range and standard deviation (or mean error) of measurements, and significance values for compared populations.


Provide an interpretation of the results and assess their significance in relation to previous work in the field. Do not repeat the results. Do not engage in general discussion beyond the scope of the experimental results. Conclusions should be supported by the data obtained in the reported study; avoid speculation not warranted by experimental results, and label speculation clearly. Discuss the significance of the data for understanding and/or treating epilepsy.


Starting on a separate page, acknowledge sources of support (grants from government agencies, privatefoundations, etc.), including funds obtained from private industry. Also acknowledge (consistent with requirements of courtesy and disclosure) participation of contributors to the study who are not included in the author list.

Disclosure of Conflicts of Interest

In addition, each author should provide full disclosure of any conflicts of interest. One of the following sentences must be included at the end of the paper: either “Author A has received support from, and/or has served as a paid consultant for .... Author B has received support from .... The remaining authors have no conflicts of interest.” Or “None of the authors has any conflict of interest to disclose.” Note: Disclosure is needed for financial income/payment from commercial sources, the interests of which are relevant to this research activity. Please identify sources from whom financial assistance/income was obtained during the period of the research activity and generation of the current report. Grants from government and/or private agencies should be identified in the Acknowledgements section. All papers must include the following statement to indicate that the authors have read the Journal’s position on issues involved in ethical publication (see below) and affirm that their report is consistent with those guidelines:

We confirm that we have read the Journal’s positionon issues involved in ethical publication and affirm that this report is consistent with those guidelines.”

□ References

Authors are responsible for the accuracy of their references. References should follow a Harvard-like format. Citation of references in the text of an article should be given by author last name (no initials) followed by the year. When two or more citations are given, list them in chronological order. When there are two authors, include both names, separated by “&”; when there are three or more names, give only the first author followed by “et al.” If there are two or more papers by the same author(s) in the same year, identify them by “a”, “b”, etc. (and be sure to include the identifying letters in the Reference List). All references cited in the text (including those included in figure legends and tables) should be listed in References.

Start the References on a separate page, and arrange citations in alphabetical order by the first author’s last name; do not number the citations. List all the authors (do not use “et al.” in the reference list). When there are two or more references to the same author(s), list them in chronological order.

For journal references, the names of authors (last name and initials) should be followed by the date (in parentheses), title of the article, journal name (in italics – use PubMed abbreviations), volume number (followed by a colon) and pages (first – last page numbers). Reference to electronic material should include author name(s), date, article title, and journal (as above); where volume and/or page numbers are not available, substitute Digital Object Identifier (DOI) number.

Sample Journal References

Journal article in a print issue

Salmenpera TM, Symms MR, Boulby PA, Barker GJ, Duncan JS (2006) Postictal diffusion weighted imaging. Epilepsy Res. 70:133–143.

Electronic reference

Baxendale S, Thompson P, Harkness W, Duncan J (2007) The role of the intracarotid amobarbital procedure in predicting verbal memory decline after temporal lobe resection. Epilepsia Published online: 25-Jan-2007; doi: 10.1111/j.1528-1167.2006.00940.x

For book references, the names of authors should be followed by the date, the full title of the book (in italics), the publisher and the location of the publisher’s office. For a chapter in a book, provide chapter authors, date, chapter title, book editors’ names, book title (italics), publisher, location of publisher’s office, and inclusive page numbers.

Sample Book References


Shorvon S (2005) Handbook of the treatment of epilepsy. Blackwell Publishing, Oxford.

Chapter in a book

Wenzel HJ, Schwartzkroin PA (2006) Morphologic approaches to the characterization of epilepsy models. In Pitkanen A, Schwartzkroin PA, Moshe SL (eds) Models of seizures and epilepsy, Elsevier Academic Press, San Diego, pp. 629–652.

Figure legends

Start figure legends on a separate page, and number each legend sequentially to conform to the figure number (e.g., Figure 1, Figure 2...). The legend should provide a brief description of the figure, with explanation of all symbols and abbreviations. Written permission to use non-original material must be obtained (from the original authors (where possible) and publishers) by the authors. Credit for previously-published material (author(s), date, journal/book title, publisher) must be included in the legend.


Tables should be formatted as the authors wish the table to appear in print. Present all tables together at the end of the manuscript, with each table on a separate manuscript page. Each table should be given a number and a descriptive title. Provide notes and explanations of abbreviations below the table, and provide clear headings for each column and row. Do not duplicate data given in the text and/or in figures. Written permission to use non-original material must be obtained (from the original authors (where possible) and publishers) by the authors. Credit for previously-published material (author(s), date, journal/book title, publisher) must be included in the table notes.


All figures should be prepared with care and professionalism. Submissions that do not comply with the following formatting requirements will be returned for correction and re-submission. Save line drawings (including line graphs, bar graphs, and simple diagrams), EEGs and other recorded traces, and diagrams as TIF files with a resolution of at least 300dpi. We recommend saving the TIF files with LZW compression (an option when you ‘save as’ in packages like Photoshop), which will make the files smaller and quicker to upload without reducing the resolution/quality. Save each TIF file with a name that includes the first author’s last name and the figure number as referenced in the text (e.g., Smith-fig1.tif). The ScholarOne Manuscripts system will merge TIF files with the text and any tables into a composite PDF for review purposes. Provide clear labels on the ordinate and abscissa. For multi-part figures, label the parts with A, B, C, etc. When relevant, include calibration information. Label figures using Gill Sans MT font; be sure that all labels are large enough to be clearly legible when the figure is reduced for publication. The maximum size of any figure in the Journal is 17 × 22.5 cm and 40 megapixels; the total number of pixels for each figure (i.e., height × width) must be less than 40 megapixels otherwise the image will not convert to PDF for review. There is no charge for color figures. We strongly encourage authors to generate figures in color (to enhance clarity of presentation and aesthetic appeal), using the following color palette:

inline image Yellow (CMYK definition: 0/11/65/0)

inline image Orange (CMYK definition: 0/58/100/8)

inline image Red (CMYK definition: 0/100/60/37)

inline image Green (CMYK definition: 27/0/95/55)

inline image Green-blue (CMYK definition: 100/0/28/65)

inline image Blue (CMYK definition: 100/46/0/0)

These colors may be viewed online at:

In order to assure consistency through the Journal, the Editors-in-Chief reserve the right to re-draw figures with appropriate font type and size, and with colors from the sample palette; authors will have an opportunity to correct inappropriate changes at the pageproofing stage.

Complex figures (including photographs, micrographs, and MR-related images), either in color, in half-tones, or in black and white, should also be submitted in TIF format with a resolution of at least 300 dpi. Such figures must also be labeled appropriately, using Gill Sans MT font. Color figures are particularly encouraged to facilitate clarity. Photographs or videos of patients should not reveal patient identity; masking eyes and/or other identifiers is compulsory unless the eyes are essential to the meaning of the photograph or video. In addition, such photographs and videos must be accompanied by a letter saying that signed consent forms authorizing publication have been obtained for all identifiable patients, and that the consents will be maintained by the author for seven years or until the patient reaches 21 years of age, whichever is longer. Do not send Epilepsia the consent forms; U.S. Federal privacy rules prohibit sending signed consent forms to Epilepsia or Wiley-Blackwell Publishing without written permission from the patient to do so.

  Supporting Information

Supporting information, to be published online only, can be submitted for review. Such material may include: additional figures, large tables, videos, etc. that cannot be accommodated within the normal printed space allocation for an article – but provide important complementary information for the reader. As determined by the reviewers and Editors, supporting information will be posted on the Wiley Online Library Epilepsia server and directly integrated into the full-text HTML article. Explicit reference to the supporting information in the main body of the text of the article is recommended, and the material must be captioned at the foot of the text, below the reference list. Supporting information will be published as submitted and will not be corrected or checked for scientific content, typographical errors or functionality. Although hosted on Wiley Online Library, the responsibility for scientific accuracy and file functionality remains entirely with the authors. A disclaimer will be displayed to this effect with any supporting information published.

Supporting Information files should be accompanied by detailed information (if relevant) about what they are and how they were created (e.g., a native dataset from a specific piece of apparatus). Acceptable formats for supporting information include:

General – Standard MS office format (Word, Excel, Powerpoint, Project, Access, etc.); PDF

Graphics – GIF; TIF (or TIFF); EPS; PNG; JPG (or JPEG); BMP; PS (postscript); embedded graphics (e.g. a GIF pasted into a Word file) are also acceptable.

Video – Quicktime; MPEG; AVI. All video clips must be created with commonly-used codecs, and the codec used should be noted in the supplementary material legend. Video files should be tested for playback before submission, preferably on computers not used for its creation, to check for any compatibility issues. Video clips are likely to be large; try to limit their size to less than 10 MB.

c. Gray Matters material


Letters, workshop reports, etc. should be given a brief title. Letters should start with the opening To the Editors:

Authors and affiliations

Provide authors’ names (first and last names, middle initial when commonly used by that author); institutional affiliation for each author (use superscripted numbers after each author’s name, and a corresponding superscripted number before each institutional affiliation); e-mail contact address for the corresponding author.

Body of submission

Letters and commentaries should be restricted to 500 words or less, unless otherwise allowed by the Editors. Figures and tables will be included only in exceptional cases. Gray Matters will not be used to publish case reports.

Tables, figures, figure legends, references, acknowledgements, disclosure of conflicts of interest, and Supporting Information – as for Full Length Original Research (see above).

(3) Details of Preparation

Detailed instructions for all aspects of electronic manuscript submission (including useful information on image files) is available on the Epilepsia ScholarOne Manuscripts website (; please click ‘Get Help Now’ at the top right-hand corner of the homepage; then click on the link ‘Author and Reviewer Guides’.

a. Text

Manuscripts should be prepared using a word processing program. Save text and tables as a Microsoft Word document. Place the lead author’s name and the page number in the upper right hand corner of each page. Begin numbering with the Title Page as #1, and number pages consecutively including references, figure legends, and tables. Text (including acknowledgements, disclosure statement, and figure legends) and references should be double-spaced, and be composed in 11–12 point font (preferably Times New Roman). When generating a revised manuscript, identify the altered portions of the manuscript with track changes.

b. Tables, Figures, and Supporting Information

See above.

Manuscript Submission

  1. Top of page
  2. Editorial Policies
  3. Types of Manuscripts
  4. Manuscript Preparation
  5. Manuscript Submission
  6. Manuscript Publication
  7. Supplement Publication
  8. Epilepsias Position on Issues Involved in Ethical Publication

(1) Online submission via Manuscript Central

Manuscripts should be submitted via the Journal’s website on ScholarOne Manuscripts at Instructions at the site will guide the author through the submission process. Separate files should be submitted for: Cover letter to editors, manuscript text (tables can be incorporated with the body of the text), each figure, supplemental material, Copyright Assignment Form (CAF), permissions to use previously-published material, patient consent declaration.

(2) Cover letter

All manuscripts should be submitted with a cover letter, addressed to the Editors-in-Chief, which explains why the manuscript should be published in Epilepsia. In particular, authors should identify novel findings, innovative approaches, and important insights that would make the manuscript of particular value to the readers of Epilepsia.

(3) Text, table and figure files

All files should be given a label that includes the first author’s last name and the nature of the file (e.g., Smith-manuscripttext.doc; Smith-Fig1.tif).

(4) Copyright Assignment Form

Authors must submit a signed Copyright Assignment Form (CAF) at the time of submission. Print out the form and sign it. Scan the signed form, save it as a PDF file, and upload it along with your manuscript files. Alternatively, the signed CAF can be faxed (+1-702-548-0706) or emailed ( to the editorial office at the time of submission of your paper. Digital signatures on PDF copyright forms are acceptable as long as the signature is clear and recognizable as the author’s signature. Your manuscript will not be considered until this form is received.

(5) Other materials/forms

At the time of submission, all other materials (e.g., permission forms, supplemental material patient consent) must be uploaded onto Manuscript Central, faxed to the editorial offce (Fax: +1-702-548-0706) or emailed to

(6) Questions/Contacts

Questions and request for assistance should be addressed to the Journal at The Managing Editor, Ms. Laurie Beninsig will in most cases be able to provide direction, or will contact the Editors-in-Chief for further assistance.

Manuscript Publication

  1. Top of page
  2. Editorial Policies
  3. Types of Manuscripts
  4. Manuscript Preparation
  5. Manuscript Submission
  6. Manuscript Publication
  7. Supplement Publication
  8. Epilepsias Position on Issues Involved in Ethical Publication

(1) Online tracking of your article

Online production tracking of your article is now available through Wiley’s Author Services. Author Services enables authors to track their article – once it has been accepted – through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive an e-mail with a unique link that enables him/her to register and have the article automatically added to the system. To facilitate this service, please ensure that you provide a complete e-mail address when submitting the manuscript. Visit for more details on online production tracking and for other publication resources (including FAQs and tips on article preparation, submission and more).

(2) Proofs

Proofs are provided electronically in PDF format using an online proofing system, and must be finalized within 48 hours of receipt. Late returns of proofs will cause substantial delay in article publication. It is the corresponding author’s responsibility to see that the proof is accurately checked and corrected, and to return the proofs promptly to avoid publication delays. Please check the spelling of coauthors’ names, text, tables, legends, and references carefully. It is the authors’ responsibility to make sure that the information is accurate. Corrections should be indicated using the PDF editor function within the online proofing system. Any issues related to the proofing process should be directed to the production editor by emailing The proof corrections stage is not the time for fine-tuning language or making any other substantive changes. Confine corrections to errors in printing; authors may be charged for major author-initiated changes.

(3) Early View

The publication-ready PDF of an article will be published initially online. Early View publication will precede print publication by a variable time period. The online publication date will be considered the official publication date. Early View published material will be indexed by PubMed, and can be cited by DOI number. In general, manuscripts will be published on Early View within 35 working days of the publisher’s receipt of the complete accepted manuscript (including CAF and permission forms).

(4) Print issue publication

Publication of an article in a print issue will typically occur after Early View publication. Hard copy (print) issues are composed for thematic coherence, and some papers may be delayed in order to be included in a relevant issue context. Print issue articles carry their electronic publication date.

(5) Public access of accepted/published articles

Prior to acceptance, articles may be shared (print or electronic copies) with colleagues; at this time the article may be posted on the author’s personal website, on his/her employer’s website, and/or on free public servers in the author’s subject area – with the acknowledgement that the article has been submitted to Epilepsia. After an article has been accepted, authors may share print or electronic copies of the article (accepted and revised to address peer review) with colleagues, and may use the material in personal compilations, other publications of his/her own work, and for educational/research purposes. Articles published in Epilepsia are freely accessible to the public – via the Wiley OnlineLibrary website – one year after publication. Epilepsia will automatically upload NIH-supported studies to PubMedCentral after a 12 month moratorium (provided the appropriate funding acknowledgement has been provided). Similarly, at this time authors may post an electronic version of the article on their own personal websites, on their employer’s website/repository, and on free public servers in the relevant subject area. Electronic versions of the accepted (or published) article must include a link to the published version of the article, together with the following text: “The definitive version is available at” Authors can also choose to make their articles open access and available free for all readers through the payment of an author fee. This facility allows authors to fulfill the requirements for studies supported by agencies requiring open access before 12 months. For full details visit

(6) Reprints

An order form for reprints will be included with the electronic transmission of initial proofs. For pricing of quantities in excess of 500 copies, please contact Emily Kaine at Wiley-Blackwell Publishing (

Supplement Publication

  1. Top of page
  2. Editorial Policies
  3. Types of Manuscripts
  4. Manuscript Preparation
  5. Manuscript Submission
  6. Manuscript Publication
  7. Supplement Publication
  8. Epilepsias Position on Issues Involved in Ethical Publication

(1) Policy

A decision to publish a supplement is based on the topic, Guest Editor, proposed table of contents and contributing authors, and availability of necessary funding. Supplement topics must be of importance to Epilepsia subscribers/readers, and supplements will be published only if there is scientific or educational rationale for combining papers on a given theme within one publication. The number and quality of the articles must be sufficient to constitute a body of important information. Each supplement will have a Guest Editor who is an expert on the theme of the supplement. The Guest Editor is responsible for compiling articles and assisting with the editorial process, and is responsible for the overall quality and integrity of the supplement. The publication of a supplement usually incurs charges, payable to Wiley-Blackwell Publishing.

(2) Publishing guidelines

Articles in a supplement are subject to the same copyright regulations and ethical publishing guidelines that apply to articles published in regular issues of Epilepsia. All supplement articles are peer-reviewed; the first level of review is carried out by the Guest Editor and his/her designates, and the second level of review is overseen by the Editors-in-Chief.

(3) Online-only and print supplements

Abstract supplements, from meetings or congresses sponsored by the ILAE or its chapters, will generally be published Online Only. Longer articles will be published in print supplements (these articles will also appear online). Print supplements may be generated from proceedings of symposia organized by an independent body of professionals in which the funding organization does not have a controlling voice on scientific content. The Guest Editor and/or organizers of such symposia should be members of ILAE chapters. Supplements from other sources – including invited supplements initiated by the Editors-in-Chief – will also be considered.

(4) Supplement content

The content of supplements must not be biased in the interest of any sponsor. Epilepsia does not permit presentations that extol a commercial product, and supplements should not be perceived as endorsing a particular product. Publication of supplements does not constitute product or sponsor endorsement by Epilepsia or ILAE. In most cases, supplements should not focus on a single product; however, when a new product is introduced, a single product focus will be considered by the Editors-in-Chief. In all cases, the content of a supplement must be determined by a body of professionals working independently of the sponsor. The Guest Editor is charged with assuring that the material presented in the supplement is not biased toward the interests of the product manufacturer.

(5) Supplement sponsorship

Most supplements require external sponsorship. When a supplement proposal is presented to the Editors-in- Chief, they will fix appropriate fees. Supplement costs may be negotiated with the Editors-in-Chief and the publisher’s supplement representative. The Editors-in-Chief may choose to publish a supplement of particular academic and/or clinical value without external sponsorship.

(6) Instructions for submitting a supplement

Agreement to publish a supplement must be obtained from the Editors-in-Chief prior to preparation and submission. Proposals for supplements should be submitted to the Editors-in-Chief ( well in advance of desired publication date, so that the proposal can be evaluated and discussed. Timing is especially critical if the supplement is linked to a symposium or congress, since rapid publication is often important to assure that the information is not out-of- date. The proposals should identify the Guest Editor and include a list of topics and potential authors. The proposal should include an estimate of supplement length so that the Editors-in-Chief can provide reasonable information about the cost of publication. The cost of any supplement, and related financial issues, should be discussed with Chris Breslin at Wiley-Blackwell Publishing ( Collection of manuscripts, as well as initial editing and reviewing, should be carried out by the Guest Editor on a schedule predetermined in discussion with the Editors-in-Chief. The Guest Editor is responsible for timely submission of articles, and should expect to assist the Editors-in-Chief in collecting final revised manuscripts (including Copyright Assignment Forms and any required permissions). Delays in submission will inevitably cause delays in publication. Supplement manuscripts (final revision) and accompanying information and forms (figures, tables, CAF, etc.) should be submitted directly to the Editor-in-Chief, not via ScholarOne Manuscript.

(7) Format of supplement articles

In general, articles should follow the format described above for Critical Reviews (in regular issues of the Journal). Contact the Editors-in-Chief for additional information and special instructions.

Epilepsias Position on Issues Involved in Ethical Publication

  1. Top of page
  2. Editorial Policies
  3. Types of Manuscripts
  4. Manuscript Preparation
  5. Manuscript Submission
  6. Manuscript Publication
  7. Supplement Publication
  8. Epilepsias Position on Issues Involved in Ethical Publication

(1) Authorship/Credit

Epilepsia follows the guidelines of the International Committee of Medical Journal Editors regarding criteria for authorship ( The author list should include those who have made substantial intellectual/conceptual contributions to the work. Such contributions should include participation in: (a) experimental design, data acquisition, and analysis and interpretation of data; (b) drafting and/or critically revising the article with respect to intellectual content; and (c) final approval of the manuscript version to be published. We strongly discourage the inclusion of “honorary” authors (individuals who are listed as authors but have not contributed to the work/manuscript – e.g., heads of departments) and “ghost” authorship (individuals who have substantively contributed to the work and/or manuscript but are not listed as authors or contributors). In cases where writing support is necessary, the writer(s) should be acknowledged in the Acknowledgements section, and the source of funding for writing support should be provided under Disclosure of Conflicts of Interest. The corresponding/submitting author must, when submitting a manuscript, give assurance that all authors have read and approved the submitted manuscript. The corresponding/submitting author should also give assurance that all authors have seen and approved the final (accepted) manuscript, and that the manuscript includes all conflict of interest declarations. All individuals who have contributed to the work but do not meet criteria for authorship should be cited in the Acknowledgement section of the manuscript.

(2) Funding

Sources of funding (for the research, data analysis, and manuscript generation) should always be disclosed in the Acknowledgements section. Sources may include government funding agencies, institutions and/or departments, private industry, and charitable organizations and foundations. Funding for all authors should be acknowledged.

(3) Procedures Involving Human or Animal Subjects

The authors should include within the manuscript an explicit statement indicating that the submitted study was approved by the relevant research ethics committee or institutional review board (IRB). When the study involves human participants (including material from human subjects), authors should also provide assurance that appropriate consent was obtained. When studies involve animal subjects, authors should provide methodological details about steps taken to minimize pain/discomfort. Such papers must contain a statement that affirms that the experimental protocols were approved by the institutional animal care and use committee (IACUC).

(4) Confidentiality

In all cases, information and images derived from individual patients must be presented with assurance of appropriate consent and with details removed that might reveal identity of the individual.

(5) Disclosure

All authors are required to disclose associations which might affect their ability to present and/or interpret data objectively, particularly financial ties to funding sources for the work under review (e.g., membership on corporate scientific boards, stock ownership, consultant arrangements, patent ownership or application, etc.). Disclosure of such associations for the Editorial personnel of Epilepsia (Editors-in-Chief, Associate Editors, Editorial Board members) will be published each year. Reviewers will also be asked to affirm that they have no conflict of interest when critiquing a manuscript.

(6) Research Misconduct (Data Fabrication/ Falsification)

Epilepsia will attempt to ensure that any allegations of misconduct are properly investigated. In the case of any allegations, authors will be given a right to respond. While the Journal is limited in its ability to investigate misconduct, we will seek COPE’s advice and alert appropriate bodies and encourage them to investigate.

(7) Plagiarism, Duplication, and Redundant Publication

Epilepsia requires that work submitted for publication is the authors’ own work and has not been misappropriated. When previously published material is used, appropriate credit must be given and written permission obtained (for use of copyrighted material). Authors must provide a signed Copyright Assignment Form (CAF) at the time of manuscript submission that warrants that the material is original with the authors. Epilepsia also explicitly discourages duplication of published material and redundant publication. The CAF indicates that the submitted article has not been previously published and is not being considered for publication elsewhere.

(8) Corrections of Erroneous Information

Authors are expected to proof-read their articles carefully before returning page proofs for publication. They should make needed corrections at this time. We recognize that it is only human to err occasionally, and the Journal is committed to correcting mistakes when those errors affect the interpretation of data or information presented in an article. Such corrections will be published in the form of an Erratum, and linked to the original article electronically. Errors that result from author oversight in the proofing process, and that do not affect data interpretation, will not be corrected.

(9) Peer Review

Epilepsia is committed to a peer-review system that is fair to the author and enhances the value of the articles published in the Journal. In order to encourage qualified reviewers to offer their time and efforts to the Journal, reviewer identity is kept confidential. Reviewers are chosen for their expertise in the field; conflicts of interest are avoided whenever the Editors are aware of such issues, and reviewers are asked to affirm that they have no conflicts of interest in reviewing a given Epilepsia manuscript. Authors are encouraged to identify specific individuals who, they believe, cannot provide unbiased review. While the Editors-in-Chief reserve the right to make the final decision to accept or reject an article, appeals will be seriously considered. Address appeals to the Editors-in-Chief, who will examine the reviews and the author responses, consult the relevant Associate Editor, and seek additional reviewer input if deemed necessary.